Vericel Enterprise Value Over E B I T D A from 2010 to 2024

VCEL Stock  USD 56.71  0.55  0.96%   
Vericel Corp Enterprise Value Over EBITDA yearly trend continues to be quite stable with very little volatility. Enterprise Value Over EBITDA may rise above 621.77 this year. From the period between 2010 and 2024, Vericel Corp, Enterprise Value Over EBITDA regression line of its data series had standard deviation of  259.76 and standard deviation of  259.76. View All Fundamentals
 
Enterprise Value Over EBITDA  
First Reported
2010-12-31
Previous Quarter
592.16372207
Current Value
621.77
Quarterly Volatility
259.75774371
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Vericel Corp financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Vericel Corp's main balance sheet or income statement drivers, such as Depreciation And Amortization of 4.9 M, Interest Expense of 630 K or Total Revenue of 207.4 M, as well as many indicators such as Price To Sales Ratio of 8.15, Dividend Yield of 0.0 or PTB Ratio of 3.9. Vericel financial statements analysis is a perfect complement when working with Vericel Corp Valuation or Volatility modules.
  
Check out the analysis of Vericel Corp Correlation against competitors.

Latest Vericel Corp's Enterprise Value Over E B I T D A Growth Pattern

Below is the plot of the Enterprise Value Over E B I T D A of Vericel Corp Ord over the last few years. It is Vericel Corp's Enterprise Value Over EBITDA historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Vericel Corp's overall financial position and show how it may be relating to other accounts over time.
Enterprise Value Over E B I T D A10 Years Trend
Slightly volatile
   Enterprise Value Over E B I T D A   
       Timeline  

Vericel Enterprise Value Over E B I T D A Regression Statistics

Arithmetic Mean36.16
Geometric Mean17.54
Coefficient Of Variation718.31
Mean Deviation166.51
Median(3.25)
Standard Deviation259.76
Sample Variance67,474
Range1K
R-Value0.36
Mean Square Error63,168
R-Squared0.13
Significance0.19
Slope21.00
Total Sum of Squares944,637

Vericel Enterprise Value Over E B I T D A History

2024 621.77
2023 592.16
2022 -106.34
2021 -391.96
2020 143.35
2019 -150.13
2018 -136.96

About Vericel Corp Financial Statements

Vericel Corp investors utilize fundamental indicators, such as Enterprise Value Over E B I T D A, to predict how Vericel Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Enterprise Value Over EBITDA 592.16  621.77 

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Vericel Corp Ord is a strong investment it is important to analyze Vericel Corp's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Vericel Corp's future performance. For an informed investment choice regarding Vericel Stock, refer to the following important reports:
Check out the analysis of Vericel Corp Correlation against competitors.
You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Vericel Corp. If investors know Vericel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Vericel Corp listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
1.045
Earnings Share
0.08
Revenue Per Share
4.685
Quarterly Revenue Growth
0.27
Return On Assets
(0)
The market value of Vericel Corp Ord is measured differently than its book value, which is the value of Vericel that is recorded on the company's balance sheet. Investors also form their own opinion of Vericel Corp's value that differs from its market value or its book value, called intrinsic value, which is Vericel Corp's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Vericel Corp's market value can be influenced by many factors that don't directly affect Vericel Corp's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Vericel Corp's value and its price as these two are different measures arrived at by different means. Investors typically determine if Vericel Corp is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Vericel Corp's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.